There are oodles of tech companies that, should they rebound over the next few quarters/years from recent crashes (once rates stabilize, global conflict subside, etc. etc.) may quite easily see a 2x or 3x from current levels.  Given the monumental impact of Poet’s technology, a 2x or 3x buyout would seem unbelievably inappropriate.  I can’t imagine how buying Teledoc Health on the dip deserves to rival potential returns on something as game-changing as Poet!